Hana Pharm Co., Ltd. (293480.KS)
KRW 10850.0
(-0.73%)
KRW 10850.0
(-0.73%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 224.45 Billion KRW | 6.46% |
| 2022 | 210.84 Billion KRW | 7.35% |
| 2021 | 196.4 Billion KRW | 10.77% |
| 2020 | 177.3 Billion KRW | 6.59% |
| 2019 | 166.34 Billion KRW | 8.84% |
| 2018 | 152.83 Billion KRW | 9.69% |
| 2017 | 139.33 Billion KRW | 11.88% |
| 2016 | 124.53 Billion KRW | 14.31% |
| 2015 | 108.94 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 57.06 Billion KRW | -0.54% |
| 2024 Q2 | 53.49 Billion KRW | -6.25% |
| 2023 Q3 | 55.6 Billion KRW | -3.06% |
| 2023 Q4 | 57.37 Billion KRW | 3.19% |
| 2023 Q1 | 54.1 Billion KRW | -0.71% |
| 2023 Q2 | 57.36 Billion KRW | 6.01% |
| 2023 FY | 224.45 Billion KRW | 6.46% |
| 2022 FY | 210.84 Billion KRW | 7.35% |
| 2022 Q4 | 54.49 Billion KRW | -0.05% |
| 2022 Q3 | 54.52 Billion KRW | 6.71% |
| 2022 Q2 | 51.09 Billion KRW | 0.73% |
| 2022 Q1 | 50.72 Billion KRW | -5.41% |
| 2021 FY | 196.4 Billion KRW | 10.77% |
| 2021 Q2 | 48.55 Billion KRW | 9.11% |
| 2021 Q1 | 44.5 Billion KRW | -8.52% |
| 2021 Q4 | 53.62 Billion KRW | 7.84% |
| 2021 Q3 | 49.72 Billion KRW | 2.42% |
| 2020 Q3 | 45.09 Billion KRW | 7.87% |
| 2020 Q2 | 41.8 Billion KRW | 0.09% |
| 2020 FY | 177.3 Billion KRW | 6.59% |
| 2020 Q1 | 41.76 Billion KRW | -4.98% |
| 2020 Q4 | 48.64 Billion KRW | 7.88% |
| 2019 Q1 | 39.79 Billion KRW | -2.93% |
| 2019 FY | 166.34 Billion KRW | 8.84% |
| 2019 Q4 | 43.95 Billion KRW | 5.83% |
| 2019 Q3 | 41.53 Billion KRW | 1.14% |
| 2019 Q2 | 41.06 Billion KRW | 3.2% |
| 2018 Q3 | 37.52 Billion KRW | -2.4% |
| 2018 Q1 | 35.85 Billion KRW | 0.0% |
| 2018 FY | 152.83 Billion KRW | 9.69% |
| 2018 Q4 | 40.99 Billion KRW | 9.23% |
| 2018 Q2 | 38.45 Billion KRW | 7.23% |
| 2017 FY | 139.33 Billion KRW | 11.88% |
| 2017 Q3 | 38.66 Billion KRW | 0.0% |
| 2016 FY | 124.53 Billion KRW | 14.31% |
| 2015 FY | 108.94 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -63.587% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 80.172% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 64.843% |
| HANDOK Inc. | 522.74 Billion KRW | 57.062% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -65.807% |
| Yuhan Corporation | 1858.98 Billion KRW | 87.926% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 66.195% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -332.021% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 84.945% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -66.375% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 39.424% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -153.356% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -32.37% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -63.587% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -187.569% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -48.577% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -156.923% |
| JW Holdings Corporation | 928.07 Billion KRW | 75.815% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 62.638% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 86.555% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 70.014% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -12.1% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -24.172% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -14.317% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 69.1% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -63.587% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 85.179% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 83.68% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 70.014% |
| Yuhan Corporation | 1858.98 Billion KRW | 87.926% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 71.756% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | 4.447% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 62.249% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 70.014% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 23.165% |
| Korea United Pharm Inc. | 278.94 Billion KRW | 19.533% |
| CKD Bio Corp. | 160.35 Billion KRW | -39.977% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 57.405% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 37.842% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | 2.577% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -12.1% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 74.487% |
| Boryung Corporation | 859.62 Billion KRW | 73.889% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -78.242% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 39.424% |
| JW Lifescience Corporation | 206.86 Billion KRW | -8.506% |